Brief Summary

To test whether the implementation of new diagnostic techniques (ultrasonography, speckle tracking, vascular stiffness study, cardiac MRI, and histologic studies) allows in CAYA (Childern, Adolescents, and Young Adults) cancer survivors a more sensitive and earlier identification of cardiovascular damage resulting from antineoplastic therapy that develops either acutely or remotely after completion of antineoplastic therapy.

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment

400

participants targeted

Target at P75+ for not_applicable

Timeline

32mo left

Started Mar 2025

Longer than P75 for not_applicable

Geographic Reach

1 country

5 active sites

Status

recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

3.8 years study duration

Study Progress30%

Mar 2025Dec 2028

Study Start

First participant enrolled

March 17, 2025

Completed

11 months until next milestone

First Submitted

Initial submission to the registry

January 26, 2026

Completed

7 days until next milestone

First Posted

Study publicly available on registry

February 2, 2026

Completed

2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2028

Expected

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2028

Last Updated

February 2, 2026

Status Verified

March 1, 2025

Enrollment Period

3.8 years

First QC Date

January 26, 2026

Last Update Submit

January 26, 2026

Conditions

Cardiotoxicity

Keywords

cardiotoxicity

Outcome Measures

Primary Outcomes (1)

Incidence of cardiovascular events in CAYA cancer survivors during treatment and follow-up
Number of cardiovascular events, defined according to ESC 2022 guidelines (Eur Heart J. 2022;43:4229-4361), detected during treatment and follow-up. Time to occurrence of events will be measured relative to pre-treatment evaluation.
From initiation of antineoplastic therapy up to 12 months post-therapy

Interventions

Parameters of vascular stiffnessDEVICE

VICORDER© is a noninvasive, quick and painless technique to be able to assess vascular elasticity and consists of placing a few sphygmomanometers (the same ones used to measure blood pressure) for a few minutes

Eligibility Criteria

Age0 Years - 18 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

Diagnosis of oncological pathology and need for antineoplastic treatment

You may not qualify if:

None

Contact the study team to confirm eligibility.